The drug, developed through a partnership between its subsidiary BioCorRx Pharmaceuticals and VDM Biochemicals Inc, could represent an alternative to naloxone in the overdose reversal market, the company said.
“Unlike naloxone, VDM-001 is a 100% pure synthetic antagonist, whereas naloxone relies on natural sources for manufacturing,” BioCorRx CEO Brady Granier said in a statement. “New preclinical data coupled with other claims from VDM, suggest therapeutic advantages of VDM-001 over naloxone and support its entry into other areas of unmet medical need. One potential benefit of VDM-001 may be a shorter and less costly manufacturing cycle. We look forward to working with VDM in order to further explore this molecule.”
The early preclinical data showed that the effects of fentanyl may be completely prevented by VDM-001, the company said. The drug was well tolerated and showed no signs of toxicity.
“We are very encouraged by the new preclinical data showing the ability of VDM-001 to block analgesic effects of fentanyl in vivo,” VDM CEO David Martirosyan said. “Based upon the data that we have gathered, new studies are currently being conducted to gain more insight into the mechanism of action of VDM-001. We believe that VDM-001 holds a significant potential to become a major lifesaving drug and have a profound impact on the lives of many people affected by the opioid epidemic. We are delighted with the current partnership in place with BioCorRx, and we welcome their continued support in our efforts to advance VDM-001.”
In 2017 alone, Martirosyan said, 28,400 people died of overdoses from synthetic opioids such as fentanyl in the US.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel